title: Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient.
abstract: Fusarium infection is known to cause major morbidity and mortality in immunocompromised hosts. We report the successful treatment of disseminated Fusarium infection with skin manifestations in a severely neutropenic, immunocompromised host with voriconazole, a new second-generation triazole. Voriconazole might be an alternative therapy for patients with neutropenia who have fusariosis that is refractory or unresponsive to amphotericin B or its liposomal formulation.
authors.affiliation: Department of Internal Medicine, Hospital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Consigny
authors.forename: Nathalie
authors.initials: N
authors.lastname: Dhedin
authors.forename: Annick
authors.initials: A
authors.lastname: Datry
authors.forename: Sylvain
authors.initials: S
authors.lastname: Choquet
authors.forename: Véronique
authors.initials: V
authors.lastname: Leblond
authors.forename: Olivier
authors.initials: O
authors.lastname: Chosidow
mesh_terms: D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D005670:Fusarium / Q000187:drug effects; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D009181:Mycoses / Q000188:drug therapy* / Q000503:physiopathology / Q000635:transmission; D009503:Neutropenia / Q000209:etiology; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D000666:Amphotericin B; D065819:Voriconazole